# FMT in IT-refractory HCC - FAB-HCC Pilot Study

> **NCT05750030** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 12 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** FMT combined with Atezolizumab plus Bevacizumab

## Key facts

- **NCT ID:** NCT05750030
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-16
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05750030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05750030, "FMT in IT-refractory HCC - FAB-HCC Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05750030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*